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1. Introduction 
1.1 Conventional antibodies 
Recombinant antibodies (Abs) are widely regarded as one of the main, if not the most 
promising tools against cancer and auto-immune, inflammatory, neurodegenerative and 
infectious diseases (Stiehm et al., 2008). Conventional antibodies are complex molecules 
consisting of pairs of heavy and light chains, whose N-terminal domain is more variable 
than the rest of the protein sequence. The antibody heavy chain usually consists of three 
constant domains (CH1, CH2 and CH3) and a variable domain (VH). The light chain has 
only two domains, the constant light (CL) and the variable light (VL). Important 
Glycosylations on the CH2 domain are necessary for antibody effector functions, such as 
Antibody-Dependent Cellular Cytotoxicity (ADCC) and Complement–Dependent Cytolysis 
(CDC), and for regulating antibody half time in serum (Fig. 1, A). Antigen-binding is 
determined by the three hypervariable Complementary Determining Regions (CDR1, CDR2 
and CDR3) present in both the VH and VL domains. These regions are located in juxtaposed 
loops, creating a continuous surface of ~ 1000 Å2 that specifically binds to the epitope in 
an antigen. Although all CDRs can potentially make contact with the antigen, CDR3 
contacts with the epitope are generally more extensive. The structural diversity of the 
antigen-binding sites of a conventional antibody depends on the size of the CDR3 in the 
VH and the conjunction with the VL at different angles and distances. These are grouped 
in three different classes, according to the size and type of antigen: cavities (fitting 
haptens), grooves (fitting peptides) and planar sites (fitting surface patches of proteins) 
(Johnson et al., 2010). 
1.2 The single variable domain of the heavy chain antibodies 
In 1993 a surprising observation was made in members of the Artiodactyl Tylopoda family 
(camelids). Next to conventional IgG antibodies, camelids also naturally produce Heavy 
Chain antibodies (HCAbs) that lack the light chain (Hamers-Casterman et al., 1993). Two 
years later, similar single chain antibodies were discovered in cartilaginous fish (sharks) 
(Greenberg et al., 1995). Although the CH2 and CH3 of the HCAbs and the conventional Abs 
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are highly homologous, there is no CH1 domain in the camelid HCAbs. The single variable 
domain, called VHH, is the only domain of HCAbs that makes contact with the antigen. 
Surprisingly, although the VHH have only three CDR regions, their affinity for antigens 
reaches the low nanomolar to even picomolar range, matching the best affinities of classical 
antibodies. When expressed as single domains (often referred to as nanobodies, Nb), the 
VHHs retain their strong epitope specificity and affinity, a feature that might be explained 
by the VHH architecture (Fig. 1, B). Just like the VHs of conventional antibodies, the amino 
acid (AA) sequence of VHHs is organised in three hypervariable regions (CDR1, CDR2 and 
CDR3) separated by four Framework regions (FR1-FR4) (Muyldermans et al., 1994). As the  
 
Fig. 1. Representative diagrams of a conventional antibody, an HCAb, and a VHH. (A) A 
conventional IgG antibody is a dimeric molecule, and each monomer comprises a heavy 
chain and a light chain. The heavy chain consists of the constant domains (CH1, CH2 and 
CH3) and the variable domain (VH). The light chain has only one conserved domain (CL) 
and a variable domain (VL). Important glycosylation sites (orange stars) are present in CH2, 
which are responsible for effector functions and the flexibility of the molecule. (B) The 
HCAb devoid of the light chain and CH1 contains the paratope (yellow box) present only in 
the single variable domain (VHH). (C) The VHH can be expressed as a prolate-shaped, 
soluble molecule of ~15 kDa. The yellow box shows the antigen binding site. (D) The VHH 
sequence is made of four Framework Regions (FR1, light gray; FR2, cyan; FR3, magenta and 
FR4, yellow), and three Complementary Determining Regions (CDR1, green; CDR2, blue 
and CDR3, red). Residues F37, E44, G47and R45 (orange) are located in the FR2 and mask a 
hydrophobic patch. C, C- terminal; N, N-terminal. The dotted red line represents a disulfide 
bond between the FR2 and the CDR3; this bond stabilizes the molecule and is present in 
dromedaries. (E) A three-dimensional structure of an anti lysozyme VHH, showing the Ig 
folding of β sheets, five strands in the front (roman numerals: I – V) and four strands in the 
back (VI – IX). The enlarged yellow box shows the antigen binding site, formed by 
juxtaposition of three CDRs. (F) The VHH shown in (F) is drawn in complex with lysozyme 
(light blue). A protruding paratope consisting mainly of CDR3 (red) recognizes and binds 
the catalytic cleft of lysozyme, inhibiting its activity. 
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AA sequence of the VHH FRs is highly similar to those of conventional VHs it was not 
surprising that the overall architecture of VHHs closely resembles that of VHs 
(Muyldermans et al., 1994). Both VHH and VH domains fold  into two β-sheets with the 
three CDRs that link these two sheets at one end of the barrel (or domain) (De Genst et al., 
2006; Desmyter et al., 1996) (Fig. 1, C,E).  However, there are striking structural differences 
between VHHs and conventional VH. Evidently, VHHs lack an interacting VL domain. 
Because of this, the hydrophobic amino acids present at the VH surface that is normally 
interacting with the VL, are substituted by hydrophilic AA (Fig.1, D). This enhances the 
solubility of VHH single domain proteins compared to engineered VH single domain 
proteins.  
The absence of the additional CDRs in VHHs is likely compensated by structural features. 
First, the CDR3 regions of camelid VHHs are generally longer (13-17 amino acids) than the 
CDR3 regions of mouse and human VHs (9-12 and 9-17 AA respectively) (Wu et al., 1993). In 
contrast to conventional Abs, in which the antigen binding surface is often a flat surface, a 
cavity or a groove, the long CDR3 loop may extend from the antigen binding surface 
(Desmyter et al., 1996). This enlarges the paratope surface and hence the potential affinity 
and repertoire of camelid HCAbs. In addition, especially in dromedaries, the CDR1 and 
CDR3 regions contain a cysteine, which allows formation of a second disulfide bridge next 
to the single disulfide bridge in conventional VHs (Muyldermans et al., 1994). This extra 
bridge likely stabilizes the CDR loops, thereby reducing their flexibility. This probably also 
contributes to the affinity (less entropy is lost upon antigen binding) and structural diversity 
of VHHs.  Long extending CDR3 loops that are stabilized by an extra disulfide bridge can 
explain the tendency of VHHs to bind to clefts and concaves surfaces more readily than 
conventional antibodies do (Fig.  1, F) (De Genst et al., 2006). Indeed comparison of multiple 
structures of hen egg white lysozyme interacting with either several conventional human 
antibodies or several camelid VHHs clearly illustrated that VHHs tends to bind to the 
concave substrate-binding pocket, whereas conventional antibodies favor epitopes on the 
“flat” surface of the antigen (Fig. 1, C). In addition, whereas each of the three CDRs of 
conventional VHs contributes considerably to the interaction with antigen, VHHs depended 
mainly on the CDR 3 loop for this interaction. Other antigens that are hard to target by 
conventional antibodies, but can be targeted by camelid VHHs are ion channels, GPCRs, 
haptens and enzymatic sites (Lauwereys et al., 1998; Rasmussen et al., 2011). 
Next to an extended CDR3, the AA sequence of the H1 loop that precedes and comprises 
CDR1 appears to be particularly more variable in camelid VHHs than in conventional VHs. 
This might be interpreted as an extension of the VHH CDR1 (Vu et al., 1997). Associated 
with this high variability in camelid VHHs, CH1 loops adopt conformations that deviate 
from the canonical H1 structures of conventional VHs (Barre et al., 1994; Decanniere et al., 
1999; Decanniere et al., 2000). Camelid VHH CH1 loops appear to fold into a more diverse 
repertoire of structures. The high variability in the AA sequence and conformations of the 
CH1 loop contribute to the VHH paratope size (850-1150 Å2), which approaches that of 
conventional antibodies (VH + VL) (Desmyter et al., 2002). Clearly, different biochemical 
and structural features of camelid VHHs compensate for the lack of a VL domain, thus 
allowing a broad repertoire of specific high affinity antigen interactions. In addition, due to 
their small size and typical extruding CDR3 regions, camelid VHH tend to bind in cavities 
that are not readily accessible for conventional antibodies. Next to these particular features, 
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VHH single domain protein is exceptionally stable and soluble, even under stringent 
conditions. As VHH are small and naturally monomeric, they can be easily formatted. In 
addition, the small size of VHHs allows them penetrate deeper into tissue (e.g. tumor tissue) 
and to occasionally cross the blood-brain barrier. On the down side, the small size of single 
domain VHH contributes to their rapid clearance from circulation. 
Using display technologies, it is possible to select VHHs from large, synthetic or naive 
libraries (Verheesen et al., 2006). The phage display generated from an immune VHH 
repertoire is the most widely and powerful technique used nowadays to rapidly select 
VHHs with the desired specificity (Arbabi Ghahroudi et al., 1997). VHH are easily produced 
in bacterial or yeast systems in miligram quantities per liter of culture. Their stability, 
solubility, ease of production and small size make them excellent candidates for multivalent 
formatting. Tailor-made constructions using VHHs as building blocks enhance the avidity of 
the molecule even in a 3 log scale, and several constructions are being tested in clinical trials 
(Els Conrath et al., 2001; Hmila et al., 2010). Their high potential as therapeutics has 
prompted the creation in Belgium of the company Ablynx in 2001. Because of the publicity 
surrounding nanotechnology and the small size of the VHH, Ablynx named the VHH as 
“Nanobody (Nb)”, and retains full intellectual property rights of the use of Nbs in 
therapeutics and diagnosis. The combined features of VHHs makes them ideal tools for 
many applications. In this chapter, we focus on the development and use of VHHs for anti-
viral therapy. It is interesting to point out that only one monoclonal antibody is used today 
(Synagis) as a therapeutic against infectious disease (Groothuis & Simoes, 1993). 
2. Influenza virus 
The main prophylactic measure against  influenza is vaccination. Therapeutic options for 
influenza are small molecule drugs targeting the viral proteins Neuraminidase (NA) or 
matrix protein 2 (M2). Influenza virus poses a great and continuous threat to humans and 
zoonotic infections also pose a dangerous challenge to human. In the last decade, two 
important viruses have emerged as pandemic or potentially pandemic outbreaks: the recent 
pandemic outbreak in the 2009 by the swine-derived H1N1 influenza virus (also called the 
Mexican Flu) and Highly Pathogenic Avian  influenza (HPAV) viruses of the H5N1 subtype, 
mainly in Asiatic countries. The 2009 H1N1 pandemic presents an interesting case. It was a 
zoonotic infection that could be transmitted between humans, but had a low mortality rate. 
On the other hand, the HPAV H5N1 virus infections present a high replication efficiency, 
broader cell tropism and possible systemic spread in patients. Fulminant pneumonia, multi-
organ failure caused by a high viral load and an intense inflammatory response (cytokine 
storm) are responsible of a mortality rate of 60 % (de Jong et al., 2006).  Vaccines to prevent 
HPAV infection are not available, but NA inhibitors (osetalmivir) are used as antiviral 
drugs. A combination of antiviral drugs and immunomodulators was used to control 
infection by HPAV H5N1 in patients, but its use was considered as a risk. On the other 
hand, passive immunization has been a successful alternative. Immunoglobulins in immune 
sera derived from animals or humans exposed to a homologous virus had been used to treat 
HPAV-infected humans (Luke & Subbarao, 2006; Zhou et al., 2007). The genetic shift and 
drift of the influenza virus underline the need for new antiviral approaches. In addition, the 
emergence of drug resistant strains poses an extra concern. The Tamiflu Resistant strain 
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(resulting mainly from the H274Y mutation, Wang et al., 2002) is evidence of the urgent need 
for new anti-influenza drugs. It is also urgent to develop new and better antiviral tools 
against the zoonotic  influenza virus, including HPAV. The characteristics of Nbs mentioned 
above makes them a potentially effective antiviral approach. Several attempts have been 
made to target conserved epitopes of proteins in the surface proteins of  influenza viruses. 
The main antigenic target in  influenza virus is the HA protein. However, the genetic shift of 
this viral protein, especially in its antigenic regions, complicates this approach. Even though 
this strategy has been successful in current seasonal vaccines, it is costly and far from 
optimal: it is not suitable for emerging pandemic viruses, as has been proven not suitable as 
an immediately available vaccine against the Mexican flu in 2009.  
2.1 Targeting influenza HA: the Nb approach 
The work of Hultberg and colleagues (Hultberg et al., 2011) is the first report of the use of 
Nb technology as an antiviral tool against influenza. That study proved the binding of Nbs 
to an  influenza protein and the neutralization of the binding of the virion to its cellular 
receptor in mammalian cells. These results are the proof of principle of the use of Nbs as 
antivirals. We discuss the most relevant results in scope of the potential further use of Nbs. 
To obtain Nbs directed against H5N1 viruses, llamas were immunized with recombinant 
H5N1 HA (H5, A/Vietnam/1203/04). The nanobody repertoire of the hyperimmune 
animals was cloned into a phage display library, and two promising HA-binding VHHs 
were isolated. The VHH of the HCab or Nb was cloned, produced as monovalent molecules, 
purified and screened for specific binding to the antigen, using as competitor the HA 
surrogate receptor fetuin. Two of the specific binders (B12 and C8) had high affinity to HA 
(KD = 9.91 and 30.1 nM) as determined by surface plasmon resonance. In addition, in a MLV 
(H5) pseudotyped neutralization assay both Nbs neutralized the parental virus 
A/Vietnam/1203/04 and also another clade 1 virus (A/Vietnam/1194/04) with a minimal 
inhibition concentration (IC50) of 75 nM. The possibility of cross reactivity among different 
H5N1 clades was also tested. The Nbs efficiency in neutralizing other clades of  influenza virus 
decreased proportionally with the antigenic distance from the virus A/Vietnam/1203/04. 
Three viruses from clade 2.2 were inhibited by the monovalent Nbs in a similar range as 
clade 1 (IC50 = 50–150 nM). On the other hand, one virus of clade 2.3.4 and one virus from 
clade 2.5 showed little or no inhibition. As mentioned above, Nbs are potentially good 
building blocks for multivalent molecules due their small size, high affinity, and efficacy as 
a production platform. Bivalent and trivalent constructs were made, based on Nb C-8, using 
Gly4/Ser linkers (GS) of different lengths. The neutralization potential of the bivalent and 
trivalent constructs was greatly enhanced against the A/Vietnam/1194/04 virus (IC50 ≤ 1 
pM). Inhibition of this clade 1 virus was confirmed by a micronetralization assay in NIBRG-
14 infected cells. NIBRG-14 is an engineered recombinant virus whose HA and NA are 
derived from the A/Vietnam/1194/04 virus. Surprisingly, in the bivalent and trivalent Nbs 
the IC50 neutralization activity (9 and 3 pM, respectively) decreased by more than 3 logs, 
compared to the monovalent Nb. These results show that the multimeric molecules 
outperformed a previously developed monoclonal antibody CR 261, against NIBRG-14 
(Throsby et al., 2008). These results were also confirmed in a hemagglutination inhibition 
assay, which showed an IC50 of 2 nM for the bivalent and trivalent construction, compared 
to 156 nm of the monovalent. 
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The multivalency format also resulted in the potential for neutralization of  influenza virus 
of different clades. For three clade 2.2 viruses, two bivalent constructions of the Nb C-8 (9 
GS and 15 GS) did not show any decrease in the IC50. On the other hand, the 10 GS linker 
trivalent molecule showed a 10 to 40-fold increase in the neutralization potential, but the 20 
GS linker trivalent showed only two-fold decrease in the IC50, or none at all.  Nevertheless, 
using the monovalent Nb the neutralization of virus from clades 2.3.4 or 2.5 was in the high 
nM range or absent, respectively. This result confirms the previous result showing that both 
bivalent and one trivalent (10GS) constructions decrease the IC50 to a low nM range. It is worth 
mentioning that the retroviral pseudovirus A/Vietnam/1194/04 and the  influenza virus 
NIBRG-14 share the same HA, but different results were obtained using the MLV 
pseudotyped neutralization assay and the infected cells microneutralization. Using 
microneutralization, the reported IC50 of the monovalent, bivalent and trivalent molecules was 
reduced ten-fold as compared to the IC50 obtained by the pseudotyped neutralization. The 
difference in sensitivity of the assays emphasizes the need to confirm the neutralization results 
of the different influenza clades in infected cells based assays. The validation of the anti HA in 
an in vivo model was performed in a mouse model by our group (Ibañez et al., 2011). 
To confirm the in vivo efficacy of the Nbs, Ibañez and colleagues used an H5N1 NIBRG-14 
mouse adapted virus strain (NIBRG-14 ma). It is important to point out that the Nbs were 
administered intranasally in all mouse experiments, in order to enhance penetration in the 
respiratory tract. Initially, to evaluate the antiviral potential using the bivalent Nb (C-8, 15 
GS) in vivo, a dose of 5 mg/kg (100 µg) was used in mice. This dose completely prevented 
loss of body weight at 4, 24 and 48 h before a challenge with 1 LD50 of NIBRG-14 ma, 
compared to the controls after 4 days of monitoring. Using the same set up, on day 4 after 
challenge, no detectable lung virus titers were observed  when mice had been treated at 4 
and 24 hrs before challenge, and at 48 hrs the titer was 50-fold lower than in controls. These 
results suggested that the bivalent Nb provide strong protection against 1 LD50, but it is 
important to consider the half life of the molecule. In previous in vitro results, the bivalent 
Nb neutralization activity was even 3 logs higher than that of the monovalent Nb, but in vivo 
there was also a significant improvement using the bivalent. The difference in virus 
neutralization capacity between the monovalent and bivalent Nbs and the minimal 
protective dose was assessed by administration of Nbs at different doses at 24 h before 
challenge with 1 LD50 NIBRG-14. The doses of Nbs ranged from 3 to 0.025 mg/kg, and 
complete neutralization was confirmed for the highest doses of both constructs. In addition, 
administration of the highest dose (60 µg, 3 mg/kg) of bivalent Nb 24 h before challenge 
with 4 LD50 also resulted in complete protection. The monovalent neutralization activity was 
dependent on the amount of Nb, but it was also statistically significant for doses of 6 or 1.2 
µg of Nb per mouse. Remarkably, very low or no lung virus titer was detected in mice 
treated with the bivalent Nb, even for the lowest doses used (2.5–0.5 µg). These results 
strongly confirmed the neutralization efficacy of the bivalent Nb when used as prophylactic 
tool against a NIBRG-14 ma, a highly pathogenic  influenza virus model. 
The therapeutic efficacy of the bivalent Nb was also tested in the same model. The 
administration of 60 µg of bivalent Nb prevented the drop in body weight and showed a 
reduction in the lung viral titers when administered 4, 24 and 48 h after 1 LD50 challenge. On 
the other hand, 72 h after challenge, the drop in body weight was similar to that of the 
controls, but statistically significant reduction in lung viral titers was observed. The decrease 
in viral titers was also confirmed by measuring the amount of viral RNA by RT-PCR. In 
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addition, 48 h after challenge of mice (treated with this dose of bivalent Nb) with 4 LD50 of 
NIBRG-14 ma, weight loss was observed and also a delay in mortality compared with the 
controls.  
The antigenic site of the HA was mapped by selecting escape mutants in the presence of the 
monovalent or bivalent Nb. Three escape mutants were selected in the presence of monovalent 
Nb, K189E/N and N154D/S mutations were found, they are contiguous in the antigenic B 
site of the HA (Wiley et al., 1981; Yamada et al., 2006). It is noteworthy to mention that 
N154D/S removes an N-glycosylation site, a possible adaptation to mask an antigenic site 
(Fig. 2). The escape mutants selected in presence of the bivalent Nb presented not only the 
K189E/N mutation, but an additional D145N mutation located in the stalk of HA2, 40 
residues upstream of the membrane anchor. The results of the hemaglutination assays and 
microneutralization experiments suggest that mutation K189N/E is necessary and sufficient 
to abolish binding to the Nb in a monovalent or bivalent conformation, indicating a close 
proximity between the antigenic B site and the receptor binding domain. Those results are 
the first one reported of the potential antiviral activity of a Nb against the  influenza virus.  
 
Fig. 2. Ribbon representation of the H5N1 HA trimeric protein. Two mutations in the head 
of the trimer confer resistance to the monovalent and bivalent VHH C-8. The mutation 
K189N/E was necessary and sufficient to prevent binding of both mono and bivalent VHHs. 
(PDB : 2IBX) 
The Nb viral neutralization activity against a trimeric HA molecule (HA) was greatly 
enhanced when presented as bivalent and trimeric molecule, but the dynamics and details 
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of the binding are not clear. It has been demonstrated that during intramolecular binding, a 
multivalent molecule has greater avidity than its monovalent counterpart. But a very 
interesting question is whether intermolecular binding occurs during Nb binding to the HA. 
In recent reports, the existence of intermolecular binding was proved to enhance an antiviral 
effect (Wang & Yang, 2010). Intermolecular binding could explain the increase in the 
neutralization activity: sterically, the hindrance of the HA for its cellular receptor is 
enhanced, and the flexibility of the HA is decreased.  
3. RSV virus 
Respiratory Syncytial Virus (RSV) infections are the leading cause of acute lower respiratory 
tract infections (ALRI) in children and associated hospitalizations world wide (Falsey et al., 
2005; Nair et al., 2010). There is no specific antiviral therapy for RSV infection available. Each 
year 66, 000 – 199,000 children die worldwide due to RSV ALRI. Most pediatric cases of fatal 
RSV infections occur in developing countries. As RSV infections do not evoke protective 
immunity, infections occur throughout life, causing severe morbidity in young infants, the 
elderly, and immune-comprised adults (Boyce et al., 2000; Falsey et al., 2005).  
Although high levels of RSV neutralizing antibodies correlate with lower frequencies of 
RSV-associated ALRI, no RSV vaccine is available (Glezen et al., 1981). However, monthly 
administration of large amounts of a humanized RSV neutralizing antibody, palivizumab 
(Synagis), reduces RSV-associated hospitalization of high risk infants by about 78-39% 
(Groothuis & Simoes, 1993). Palivizumab is currently the sole monoclonal antibody that is 
approved for preventing viral infection. Palivizumab blocks fusion of the RSV membrane 
with the membrane of the target cell by binding to the RSV fusion protein (F) (Huang et al., 
2010). However, due to the high cost of palivizumab, there is an urgent need for new anti-
virals that can prevent or treat RSV infections. RSV neutralizing Nbs have been developed 
as an alternative to existing antibodies (Hultberg et al., 2011). 
3.1 RSV binding VHHs antiviral effect: comparison with Synagis Mab. 
To investigate if Nbs could be used for antiviral therapy, Nbs that bind to the palivizumab 
epitope were developed. For this purpose, two llamas were immunized with recombinant 
RSV A F protein (RSV FTM-) lacking the transmembrane region (Hultberg et al., 2011). This 
protein folds into trimers that resemble the native RSV F protein in its post-fusion 
conformation (Ruiz-Arguello et al., 2004). Remarkably, RSV FTM- proteins can be readily 
recognized by RSV F neutralizing antibodies that, just like palivizumab, bind to the 
antigenic site II (McLellan et al., 2011; Swanson et al., 2011). In this way, RSV FTM- 
immunization can potentially induce RSV F antigenic site II specific camelid HCAbs. HCAbs 
that specifically bind to the RSV F antigenic region II were enriched by biopanning using 
RSV FTM- protein and competitive elution in the presence of excess of palivizumab antibody. 
From these HCAbs, VHHs (or Nbs) were produced and tested for binding to the RSV FTM- 
protein. Twelve VHHs that bound to the RSV F protein were tested for neutralization of 
RSV Long strain (RSV A subtype) virus in a micro-neutralization assay. Two VHHs (RSV-C4 
and the RSV-D3) could neutralize RSV in the high nanomolar range (IC50: 640 nM and 300 
nM, respectively), which is similar to the neutralization activity as the Synagis Fab (IC50: 
549.2 nM) and about 100-fold less effective than the Synagis Mab (IC50: 3.02 nM). However, 
in contrast to palivizumab, neither RSV-C4 nor RSV-D3 VHHs could neutralize RSV B 
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subtype virus in vitro. On the contrary, another VHH (RSV-E4) could neutralize RSV B 
infection to some extent.  
The epitopes of different VHHs were determined by antibody competition assays and 
diverse antibody escape RSV mutants.  Whereas RSV-C4 and RSV-D3 VHHs readily 
competed with palivizumab for binding to recombinant RSV FTM- or inactivated RSV 
virions, RSV-E4 competed with 101 Fab, which is known to bind to the antigenic region IV-
VI (Wu et al., 2007). These data are in line with the observation that AA substitutions within 
antigenic regions II and IV-VI, respectively, affected the binding of both RSV-D4 and RSV-
C3 VHHs and RSV-E4 VHH. These data strongly suggest that both RSV-C3 and RSV-D4 
bind to antigenic region II (palivizumab epitope) (Crowe et al., 1998) whereas RSV-E4 VHH 
binds to antigenic regions IV-VI, explaining the observed differences in neutralization.  
The affinity of the three VHHs, Synagis Mab and Synagis Fab was determined by Surface 
Plasmon Resonance using recombinant RSV F TM- as bait. The KD of RSV-D3, RSV-E4 and 
RSV-E4 were in the low nanomolar range: 9.24 nM, 1.78 nM and 0.45 nM, respectively. 
Although RSV-D3 was more effective than RSV-C4 at neutralizing RSV A, it had a lower 
affinity for FTM- than RSV-C4. However, the efficient binding of RSV-E4 VHH to a 
neutralizing epitope (antigenic region IV-VI) was not associated with neutralization of RSV 
A. This suggests that the affinity of VHHs for the recombinant RSV FTM-, which likely 
represents the F protein in its post-fusion conformation, does not correlate directly with 
neutralization of living RSV (Table 1.) 
 
*Obtained from two different cell based assays, microneutralization and plaque assay 
Table 1. Inhibition and protection of the RSV virus A binding by Nb RSV-D3. ND = not 
determined. 
The avidity of a binding molecule can be increased by using a multivalent format (Rudge et 
al., 2007; Wang & Yang, 2010). To increase the antiviral potential of RSV-D3 we formatted it 
into a bivalent molecule, by using a flexible linker, Gly4/Ser (GS). Surprisingly, bivalent 
RSV-D3 VHHs with GC linkers of different sizes neutralized RSV A Long virus between 
2421 and 4181 times more efficient than monovalent RSV-D3 VHHs, reaching picomolar 
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range (IC50: 190-110 pM). In contrast, Synagis Mab was only 200 times more efficient in 
neutralizing RSV A virus (IC50: 6.5 nM) than its corresponding Fab fragment. In this way, 
bivalent RSV F specific VHHs outperform the Synagis antibody in RSV neutralization. 
Moreover, in contrast to its monovalent format, bivalent RSV-D3 could also neutralize RSV 
B1 strain virus. Also, neutralization was notably boosted against RSV A and B virus 
subtypes by linking two different VHHs (RSV-D3 and RSV-E4) which target different 
epitopes. The enhancement of the activity by linking two VHHs is likely due to the 
flexibility of the linker. Experiments aiming to characterize the binding dynamics of the 
RSV-D3 to the F protein are necessary for characterizing intra- or intermolecular binding. 
The RSV F is responsible for fusion of the viral lipid membrane with the host membrane, but 
also participates in attachment of the RSV virions to target cells. In addition, it was recently 
demonstrated that RSV F protein can bind to nucleolin expressed at the surface of target 
cells, and that this interaction is crucial for RSV infection in vitro and in vivo (Tayyari et al., 
2011). After viral attachment, the RSV F protein mediates fusion of the viral membrane with 
the plasma membrane of the target cell, thereby releasing the viral genome into the 
cytoplasm of the host cell. This process involves a series of conformational changes in the F 
protein from a metastable pre-fusion to a stable post-fusion conformation. We recently 
demonstrated that bivalent RSV-D3 VHHs can prevent RSV infection both before and after 
viral attachment and can inhibit syncytia formation, but cannot hamper RSV attachment 
(Schepens et al., 2011). Together, these observations constantly indicate that, by a similar 
mechanism as palivizumab, bivalent RSV-D3 VHHs prevent RSV infection by blocking 
fusion. Although the conformations of the RSV F antigenic regions II and IV-VI are 
maintained in the post-fusion form, it is more plausible that the RSV VHHs block viral 
fusion and syncytia formation by binding to the RSV F protein in either its pre-fusion or 
intermediate conformations (Fig. 3). Possibly, binding of the VHHs to the antigenic region II 
interferes with the conformational changes of the F protein that are required for fusion. 
Immune compromised Balb/c mice (cyclophosphamide treatment) were used to test whether 
bivalent RSV-D3 VHHs can protect against RSV infection in vivo (Schepens et al., 2011). As 
VHHs are known to remain active in the respiratory tract after nebulisation, bivalent RSV-D3 
and control VHHs were administered intranasally (patent application WO 2009/147248). 
Prophylactic treatment of mice with 5 mg/kg of bivalent RSV-D3 VHH or palivizumab 
reduced RSV pulmonary titers below the detection limit of the RSV plaque assay. This strong 
reduction was confirmed by qPCR analysis. Remarkably, as low as 0.6 mg/kg bivalent RSV-
D3 could prevent or strongly reduce (at least 100-fold) pulmonary RSV replication. In 
comparison, monovalent RSV-D3 VHH protected against pulmonary RSV replication about 25 
times less efficiently than its bivalent counterpart. For prophylactic treatment to be valuable, 
even if is easy to administer, its effect should be long lasting. We demonstrate that intranasal 
administration of bivalent RSV-D3 VHHs can protect against RSV infection for at least 48 
hours. Prophylactic treatment with palivizumab in high risk infants reduces RSV associated 
hospitalization, but no effective therapeutic is available. Therefore, RSV-D3 VHHs were also 
evaluated as therapeutic treatments. Intranasal administration of RSV-D3 VHHs 4 or 24 hours 
after infection strongly reduced pulmonary RSV replication (at least 100-fold). Plaque assays 
also indicated that administration of bivalent RSV-D3 VHHs 72 hours after RSV treatment can 
reduce pulmonary RSV replication. However, the lung homogenates used to quantify the 
pulmonary RSV titer in mice that were treated 72 hours after infection still contained 
neutralizing RSV VHHs. Therefore, it is not clear to which extent treatment at this time point 
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reduced RSV replication in vivo. The potential of bivalent VHHs for preventing morbidity and 
pulmonary inflammation upon RSV infection was assessed in a non immunocompromised 
mouse model. Prophylactic administration of bivalent RSV-D3 VHHs (1 mg/kg) completely 
prevented body weight loss and pulmonary cell infiltration that was observed in mice treated 
with control VHHs. Therapeutic treatment with bivalent RSV-D3 VHHs 24 h after infection 
partially reduced body weight loss and pulmonary cell infiltration. These observations confirm 
the in vivo antiviral potential of neutralizing VHHs.  
 
Fig. 3. Ribbon representation of the structure of the RSV F protein trimer in its post-fusion 
form. The head and stalk of this recombinant protein are depicted, lacking the fusion 
peptide, transmembrane region and cytoplasmic domain. The immunogenic epitopes 
recognized by Mab 101F (site II) and palimuzab (site IV-VI) are in red and blue, respectively, 
and the rest of the F protein is in green. The RSV-D3 and RSV-C4 resistant in vitro escape 
mutants are shown in yellow. Mutations I432T, K433T and S436F in site II disrupt the 
binding of the RSV-C4. The K262Y, N268I and K272E in the site IV-IV result in loss of 
binding of the RSV-D3 molecule. (PDB: 3RKI). 
Currently Ablynx is preparing a phase I clinical trial to evaluate the safety of a trivalent RSV 
neutralizing VHH format consisting of three identical VHHs. Preclinical evaluation of this lead 
candidate can readily neutralize a broad spectrum of clinical RSV A and RSV B subtype 
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viruses more efficiently than Synagis (abstract, 7th international RSV symposium, Rotterdam, 
2010). In vivo studies demonstrated that both prophylactic and therapeutic treatment with this 
RSV neutralizing VHH can readily reduce RSV replication in the upper and lower respiratory 
tract of cotton rats (abstract, 7th international RSV symposium, Rotterdam, 2010).  
In summary, neutralizing RSV VHHs are promising new candidates as anti-RSV 
therapeutics for different reasons. First, VHHs allow versatile formatting including the 
creation of multivalent formats by the use of flexible linkers. This feature enabled the 
creation of bivalent and trivalent VHH which can neutralize RSV at picomolar range, more 
than 1000-fold more efficient than their monovalent counterpart. Second, by linking two 
different VHHs which neutralize different virus strains (such as the RSV A versus the RSV B 
subtype strains) cross-reactive VHH constructs can be obtained. Moreover, as a result of 
avidity effects, cross linking VHH with different specificity can considerably improve the 
neutralizing activity. Third, the VHHs small size and protruding paratopes can contribute to 
its neutralization activity. As structural models and electron microscopic analysis indicate 
that the antigenic region II is located at the side of the RSV F protein trimer, at the dense 
surface of RSV virions, this region is likely more accessible for small and flexible VHH 
formats than for large and more rigid antibodies (McLellan et al., 2011; Ruiz-Arguello et al., 
2004) (Fig. 3). Fourth, due to their high stability at stringent conditions, VHHs can be 
administered via nebulisation, which allows a rapid accumulation of high amounts of 
neutralizing VHH at the site of respiratory viral infections. In addition, due to the high 
stability of VHHs and the ease of intranasal or pulmonary administration, VHH therapy 
could potentially be applied more generally, even in developing countries. 
4. Rabies virus 
Rabies virus (RV) is a single stranded RNA virus of the Rhabdoviridae family, genus 
Lyssavirus. Infection with RV in humans causes acute encephalitis, with a mortality rate of 
almost 100%. It is transmitted to humans by bites from a carnivore or a quiroptera vector 
and most cases occur in Asia or Africa. The long incubation period following infection by 
RV presents a paradox, because of the absence or very weak antiviral immune response 
(Johnson et al., 2010). The small amount of virus inoculated after infection and the 
neurotropism of RV are believed to contribute to the absence of effective antibodies in the 
patient. After the bite, wound cleaning can reduce the chances of a productive infection in 
humans. Passive immunization and vaccination promptly after exposure is the only 
effective therapeutic tool available now. Modern vaccines are inactivated virus produced 
from continuous cell cultures, like the vaccine by Aventis Pasteur (human diploid cells). 
Nevertheless, in underdeveloped countries, the established RV therapy (attenuated virus, 
Mab anti RV) is too expensive for most of the population. RV has a genome of 12 kDa 
coding for 5 proteins: nucleoprotein, phosphoprotein, matrix, RNA-dependent RNA 
polymerase and the Glycoprotein (RVG). In the virus particle, the RVG is the only viral 
protein exposed as a trimeric spike, and it is responsible for recognition of cellular receptors, 
virulence and antigenicity.  
4.1 Nbs present a broad protection against Rabies virus 
For more than 25 years, two well-defined antigenic sites in the RVG have been characterized 
by Mabs: antigenic sites II and III (Lafon et al., 1990). Other epitopes have also been 
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characterized, but their contribution to antigenicity is minor. Antigenic site III extends from 
330 to 340 amino acids and is linear (Seif et al., 1985). Mutations in this site affect virulence 
and the host range of the virus. On the contrary, antigenic site II is conformational and 
discontinuous and is determined by two regions, amino acids 34-42 and 198-200. Site II is 
responsible for about 70 % of the known Mabs against RVG (Benmansour et al., 1991). 
RGV is an interesting target for the VHH platform because alternative cost effective 
antirabies tools are needed. By using an approach similar to those previously discussed for  
influenza and RSV, a llama was immunized with recombinant RVG and five VHHs were 
obtained (Rab – E8, H7, F8, E6 and C12). The neutralizing activity of those VHHs was 
validated against 10 Rabies genotype 1 viruses: 3 laboratory strains (CVS-11 as prototype, 
ERA, CB-1) and 7 field isolates and one rabies genotype 5 virus (EBL-V1) was included to 
validate broad cross neutralization. A cell based assay was used, the Rapid Fluorescent 
Focus Inhibition Test (RFFIT) (Vene et al., 1998). This assay has been internationally 
recognized as the in vitro standard for testing virus neutralizing antibodies. Mab 8-32, which 
recognizes antigenic site II of RVG was also included as positive control (Montano-Hirose et 
al., 1993). VHHs F8, E6, H7 and C12 neutralized the genotype 1 strains: CB-1 and ERA with 
an IC50 in the low nanomolar range and the CVS-11 strain in the low to high nanomolar 
range. They could also neutralize several RV field isolates. On the other hand, E8 efficiently 
neutralized only CB-1 and CVS-11, in the low and high nanomolar range, respectively. C12 
and E6 had better neutralization activity than Mab 8-2 against the ERA and CB-1 strains. Using  
a similar approach as described above for influeza and RSV, the authors also generated the 
bivalent against the Rabies genotype 1 CVS -11 and the genotype 5 EBLV-1. Bivalent 
monoparatopic VHHs were constructed using a Gly4/Ser linker, using the 12, H7, E8 and F8 
VHHs. The neutralization IC50 of these constructions was reduced from two to 180-fold 
relative to the monovalent protein, indicating enhancement of the neutralization. Nevertheless, 
the best results were obtained when biparatopic molecules were used. The E6/H7 and the 
H7/F8 molecules increased the neutralization potency by a 2 log factor, while the E8/H7 
increased 3 log-fold, compared with the monovalents. E8/H7 even outperformed Mab 8 -2 
against the CVS-11. On the contrary, in the case of the genotype 5 strain EBLV-1, the 
monovalent molecules showed modest neutralization or none at all. The enhanced 
neutralization of biparatopic molecules was confirmed by E8/C12, which presented an 
increase in the neutralization potential of 147-fold (IC50 = 3.76 nM) relative to the 
monovalent moiety, but not as low as Mab 8 – 2 (IC50 = 0.12 nM). The results of competition 
assays of the 5 VHHs against the Mab 8- 2 showed that E6, E8, F8 and H7 compete for the 
same epitope. On the other hand, C12 did not compete which indicates that it recognizes a 
different epitope. The difference in epitope recognition could be one of the causes of the 
strong and broad effect of biparatopic molecules, especially for E8/C12. Experiments using 
VHHs against Rabies mutant virus, carrying substitutions in the known residues in the 
antigenic site II could localize the exact binding sites of these new antibodies. For example, it 
has been reported that substitution K198E of the glycoprotein abolish the binding of the 
Mab 8–2 (Montano-Hirose et al., 1993). Unfortunately, the crystallographic structure of the 
RVG protein has not been reported. The use of vesicular stomatitis virus glycoprotein is 
accepted as a modeling reference and as a surrogate template for RVG structure (Cibulski et 
al., 2009; Tomar et al., 2010). We used the alignment of this protein with the RVG as reference 
to show the possible structure of antigenic site II (Fig. 4). The purpose of this estimate is to 
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show the tendency of the VHHs to recognize conformational rather than linear epitopes. In 
line with the results of the neutralizing VHHs against  influenza and RSV, the results of the 
broadness and the strong potency against both RV genotypes indicate the RV neutralizing 
VHHs as a promising. Nevertheless, in contrast with the previous cases of the  influenza and 
RSV VHHs, there is not in vivo validation of the RV neutralizing VHHs available. 
 
Fig. 4. Schematic representation of the vesicular stomatitis virus protein G trimer. This 
protein is taken as reference to depict the amino acids corresponding to the antigenic site II 
of the Rabies Virus glycoprotein (residues 34-42, and 198-200, in blue). The localization of 
the K198E mutation that prevents the binding of the Mab 8-2 is shown in red. The VHHs E8, 
F8, E6 and H7 compete with the Mab 8- 2 for the binding, which means that their epitopes 
might be within antigenic site II. (PDB: 2CMZ). 
5. Conclusion  
The Nb platform is a new and promising antiviral tool. The ease of producing Nbs in 
bacterial and lower eukaryotic cells, and the possibility of producing tailor-made 
constructions makes them an attractive and cost effective alternative to some established 
antiviral drugs. This approach may be useful for the treatment of infectious orphan diseases 
(including viral) and in developing countries, where the “standard” prophylaxis or therapy 
is prohibitively expensive or not available. In this work we have discussed findings on 
recently developed Nbs directed against three viruses affecting humans:  the generation and 
in vitro validation of the Nbs or VHHs against  influenza H5N1, RSV and RV (Hultberg et al., 
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2011); as well as the in vivo validation of the  influenza HA binding VHH (Ibañez et al., 2011) 
and RSV (Schepens et al., 2011). In the case of protection against  influenza infection the 
bivalent format of the Nbs proved superior in vitro and in vivo. But, as indicated by the 
successful in vivo validation of one of the H5N1 strains, it is imperative to extend this 
validation to other  influenza strains. Furthermore, it would be worthwhile to isolate and 
characterize Nbs that recognize conserved domains in HA, such as the stalk. In line with the  
influenza results, the activity of RSV and RVG neutralizing Nbs was significantly higher for 
the bivalent than the monovalent format: both the cross neutralization activity and potency 
were higher. Those results manifest the advantages of using a multimeric format against 
multimeric viral targets. The enhanced antiviral potential of the multimeric format could be 
due to increased avidity and/or the intra- or intermolecular binding could contribute in the 
enhancement. Experiments to assess the binding mechanism could lead to further 
improvements. The results overall confirm two important points: the high potential of the 
Nbs as prophylactic and therapeutic tools, and the possibility of using Nbs directed against 
other infectious diseases. There is limited function and sequence similarity among the three 
proteins used as antigens (HA, RSVF and RVG) other than their trimeric architecture and 
antigenicity. Nevertheless, the HA and the RVG are functionally similar and both are 
involved in the cellular receptor binding, whereas RSVF participates also in virion receptor 
binding, it s main function is in membrane fusion. In all three cases, showed capacity to 
neutralize the viral target by blocking binding or hampering necessary conformational 
changes, indicating the great versatility and efficiency of the antiviral discussed here.  In 
competition assays, the recognition of non conventional epitopes by these antiviral was not 
observed, but could be the focus of research. Nbs recognized well known antigenic sites that 
are also targeted by Mabs. The HA, RSV F and RVG are not enzymes, and lack extensive 
antigenic clefts. This could be one reason why Nbs showed preference for recognition of 
“classical” epitopes in these viral proteins. If the presence of antigenic clefts could lead to 
recognition of non “classical” epitopes in the viral proteins, targeting viral enzymes could be 
an interesting approach. Enzymes such as the  influenza Neuraminidase are potential 
targets. This viral sialidase presents a catalytic cleft, in which the framework and substrate 
contact residues are conserved in most of the  influenza strains. The coming years will 
probably bring potent novel anti-viral Nbs directed against different viruses and it is likely 
that some of these Nbs will reach clinical trials.  
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